<DOC>
	<DOCNO>NCT00179998</DOCNO>
	<brief_summary>This study find whether Pulmozyme effective clearing mucus airways child cystic fibrosis le 3 ½ year age . Pulmozyme give use nebulizer widely use old child adult cystic fibrosis . In adult old child , study show daily use Pulmozyme improves lung function decrease number lung infection require hospital treatment . Pulmozyme approve Food Drug Administration use child 5 year old adult cystic fibrosis . Pulmozyme also approve FDA use child cystic fibrosis le 5 year old base upon study show safe age group get airway tubes well infants toddler old child adult . Currently Pulmozyme widely use child cystic fibrosis young 5 year study clearly show inhale Pulmozyme daily improves lung function improve clearance mucus airway tubes young child . This study measure whether Pulmozyme improve lung function mucous clearance lung child cystic fibrosis le 3 ½ year age . This study compare Pulmozyme placebo . During study infant young child cystic fibrosis treat Pulmozyme 6 month placebo 6 month . The study medicine inhale home day nebulizer period one year . Half child treat Pulmozyme first 6 month study half receive placebo . At 6 month point group receive Pulmozyme change placebo group receive placebo change Pulmozyme . The order 6 month treatment period randomize . This study blind . The study doctor staff know receive Pulmozyme placebo time study . Whether Pulmozyme work measure use infant lung function test special 3-D x-ray child 's chest ( high resolution CT HRCT ) begin study , 6 month 12 month start study . The study change regular clinical care .</brief_summary>
	<brief_title>Effectiveness Pulmozyme Infants With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Age &lt; 30 month Diagnosis CF base clinical feature consistent CF well 1 2 follow criterion : ) two sweat chloride &gt; 60 mEq/L ( quantitative pilocarpine iontophoresis ) , b ) genotype 2 identifiable mutation consistent CF . Informed consent parent legal guardian Previous treatment Pulmozyme Hospitalization treatment IV antibiotic 14 day initial study visit Acute intercurrent respiratory infection , define follow symptom within precede 48 hour : 1 ) fever &gt; 38 degree C , 2 ) new onset coryza upper respiratory symptom , 3 ) increase cough , wheeze , respiratory rate History adverse reaction sedation Oxyhemoglobin saturation &lt; 90 % room air Severe upper airway obstruction determine site PI ( severe laryngomalacia , markedly enlarge tonsil , significant snoring , diagnose obstructive sleep apnea ) Hemodynamically significant congenital heart disease diagnose arrhythmias History hemoptysis History previous pulmonary air leak ( pneumothorax ) Diagnosed seizure disorder necessitate current anticonvulsive therapy . A history febrile seizures exclusion criterion . Use Investigational drug ( ) within 60 day 5 halflives enrollment study . Known allergy Chinese Hamster Ovaryderived biological product component placebo active drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>30 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Infants</keyword>
	<keyword>Children</keyword>
	<keyword>Pulmozyme</keyword>
	<keyword>Pulmonary function</keyword>
	<keyword>Computed tomography</keyword>
</DOC>